Latham & Watkins advised the underwriters in the offering, and Wilmer Cutler Pickering Hale and Dorr represented Akebia Therapeutics, Inc. Proskauer Rose advised Akebia Therapeutics, Inc....
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented KALA BIO, Inc. in the transaction. KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company, announced it had entered into...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr represented Trevi Therapeutics, Inc. in the offering, and Covington & Burling represented the underwriters. Trevi Therapeutics, Inc. (Nasdaq: TRVI), a...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Ratio Therapeutics Inc in the transaction. Ratio Therapeutics Inc, a pharmaceutical company, announced its exclusive worldwide license and collaboration...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Dyne Therapeutics, Inc. on the offering, and Cooley advised the underwriters. Dyne Therapeutics, Inc. (Nasdaq:DYN) announced the closing of...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Apellis Pharmaceuticals, Inc. on the deal, while Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo and Proskauer Eose advised Sixth...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Dyne Therapeutics, Inc., and Cooley advised the underwriters. Dyne Therapeutics, Inc. (Nasdaq:DYN) (“Dyne”) announced the closing of an underwritten public offering...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Gemini, while Goodwin Procter advised Disc Medicine. Fried, Frank, Harris, Shriver & Jacobson acted as counsel to SVB Securities...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Apellis Pharmaceuticals on the deal. Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Beam Therapeutics Inc. (Nasdaq: BEAM), announced that they...
You must be a Standard 1 Year member to access this content.
